Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sellas Life Sciences Group Inc (SLS)

Sellas Life Sciences Group Inc (SLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 247,849
  • Shares Outstanding, K 142,442
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,880 K
  • EBIT $ -27 M
  • EBITDA $ -27 M
  • 60-Month Beta 2.51
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.77

Options Overview Details

View History
  • Implied Volatility 157.09% (-29.82%)
  • Historical Volatility 91.89%
  • IV Percentile 65%
  • IV Rank 24.81%
  • IV High 369.63% on 04/07/25
  • IV Low 86.98% on 08/15/25
  • Expected Move (DTE 12) 0.3655 (21.01%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 7,278
  • Volume Avg (30-Day) 7,408
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 536,407
  • Open Int (30-Day) 533,905
  • Expected Range 1.3745 to 2.1055

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +1,248,850.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3900 +25.18%
on 12/02/25
1.8399 -5.43%
on 12/04/25
+0.0600 (+3.57%)
since 11/05/25
3-Month
1.3900 +25.18%
on 12/02/25
2.4800 -29.84%
on 10/20/25
-0.1700 (-8.90%)
since 09/05/25
52-Week
0.7720 +125.39%
on 12/13/24
2.4800 -29.84%
on 10/20/25
+0.6400 (+58.18%)
since 12/05/24

Most Recent Stories

More News
SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

– Hosted Virtual R&D Day Highlighting GPS and SLS009 Programs in AML – – Positive Phase 2 Data for SLS009 in R/R AML Accepted for Presentation at ASH 2025; Initiation of Trial Including Newly...

SLS : 1.7400 (unch)
SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development...

SLS : 1.7400 (unch)
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development...

SLS : 1.7400 (unch)
Targeted Cell Therapies and Precision Degraders Drive $404B Cancer Market Expansion

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists engineered invisible immune cells in October 2025 that hide from rejection while destroying tumors[1],...

IOVA : 2.20 (unch)
GMAB : 31.74 (-0.87%)
NRIX : 18.09 (+0.39%)
GTBP : 0.6094 (-3.24%)
SLS : 1.7400 (unch)
SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025

NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development...

SLS : 1.7400 (unch)
SELLAS Extends Times Square Sublease Agreement

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

SLS : 1.7400 (unch)
SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update

NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development...

SLS : 1.7400 (unch)
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development...

SLS : 1.7400 (unch)
SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

- Positive IDMC Recommendation to Continue Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in AML Without Modification; Final Analysis Anticipated by Year-end 2025 – - Reported Positive Phase...

SLS : 1.7400 (unch)
SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

-        Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events        - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’...

SLS : 1.7400 (unch)

Business Summary

SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present...

See More

Key Turning Points

3rd Resistance Point 1.9067
2nd Resistance Point 1.8533
1st Resistance Point 1.7967
Last Price 1.7400
1st Support Level 1.6867
2nd Support Level 1.6333
3rd Support Level 1.5767

See More

52-Week High 2.4800
Fibonacci 61.8% 1.8275
Last Price 1.7400
Fibonacci 50% 1.6260
Fibonacci 38.2% 1.4245
52-Week Low 0.7720

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar